Measurement of antipsychotic-induced side effects: Support for the validity of a self-report (LUNSERS) versus structured interview (UKU) approach to measurement

Human Psychopharmacology

Volumn 18, Issue 5, 2003, Pages 405-411

  Lambert, T J R ^a   Cock, N ^b   Alcock, S J ^a   Kelly, D L ^c   Conley, R R ^c  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b Mills Street Centre ^*  (Australia)

^c MARYLAND PSYCHIATRIC RESEARCH CENTER   (United States)

Author keywords

Antipsychotics; Extrapyramidal symptoms; Rating scales; Schizophrenia; Side effects

Indexed keywords

NEUROLEPTIC AGENT;

ADULT; AGED; AKATHISIA; ARTICLE; ASTHENIA; AUSTRALIA; AUTONOMIC NEUROPATHY; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION FUNCTION; EXTRAPYRAMIDAL SYMPTOM; FATIGUE; FEMALE; GASTROINTESTINAL SYMPTOM; HEADACHE; HOSPITAL PATIENT; HUMAN; HYPERKINESIA; INTERVIEW; LETHARGY; MALE; MEASUREMENT; MENTAL DISEASE; MENTAL HEALTH SERVICE; MUSCLE DISEASE; OPEN STUDY; OUTPATIENT CARE; POLYURIA; PRIORITY JOURNAL; PSYCHOLOGIC ASSESSMENT; PSYCHOSIS; RATING SCALE; RESTLESSNESS; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SCORING SYSTEM; SELF REPORT; SKIN DISEASE; SLEEP DISORDER; SYMPTOMATOLOGY; VALIDATION PROCESS; VERTIGO; XEROSTOMIA;

ADOLESCENT; ADULT; AGED; ANTIPSYCHOTIC AGENTS; DATA COLLECTION; DRUG MONITORING; FEMALE; HUMANS; INTERVIEWS; MALE; MIDDLE AGED; PSYCHIATRIC STATUS RATING SCALES; REPRODUCIBILITY OF RESULTS;

EID: 0041310975     PISSN: 08856222     EISSN: None     Source Type: Journal    
DOI: 10.1002/hup.495     Document Type: Article

References (14)

1. Amador XF, Strauss DH, Yale SA, Flaum MM, Endicott J, Gorman JM. 1993. Assessment of insight in psychosis. Am J Psychiatry 150: 873-879.
2. Bond WS, Hussar DA. 1991. Detection methods and strategies for improving medication compliance. Austr J Hosp Psychiatry 48: 1978-1998.
3. Buchanan A. 1992. A two-year prospective study of treatment compliance in patients with schizophrenia. Psychol Med 22: 787-797.
4. Day JC, Wood G, Dewey M, Bentall RP. 1995. A self-rating scale for measuring neuroleptic side-effects. Validation in a group of schizophrenic patients. Br J Psychiatry 166: 650-653.
5. Donohoe G, Owens N, O'Donnell C, et al. 2001. Predictors of compliance with neuroleptic medication among inpatients with schizophrenia: a discriminant function analysis. Eur Psychiatry: J Assoc Eur Psychiatrist 16: 293-298.
6. Fleischhacker WW, Meise U, Gunther V, Kurz M. 1994. Compliance with antipsychotic drug treatment: influence of side effects. Acta Psychiatrica Scand 89: 11-15.
7. Green JH. 1988. Frequent rehospitalization and noncompliance with treatment. Hosp and Commun Psychiatry 39: 963-966.
8. Hoge SK, Appelbaum PS, Lawlor T, et al. 1990. A prospective, multicenter study of patients' refusal of antipsychotic medication. Arch Gen Psychiatry 47: 949-956.
9. Kerwin R, Taylor D. 1996. New antipsychotics: a review of their current status and clinical potential. Drug Ther 6: 71-82.
10. Lingjaerde O, Ahlfors UG, Bech P, Dencker SJ, Elgen K. 1987. The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross sectional study of side effects in neuroleptic treated patients. Acta Psychiatrica Scand 76: 1-100.
11. Remington G, Kapur S. 2000. Atypical antipsychotics: are some more atypical than others? Psychopharmacology 148: 3-15.
12. Van Putten T. 1974. Why do schizophrenic patients refuse to take their drugs? Arch Gen Psychiatry 31: 67-72.
13. Voruganti L, Heslegrave R, Awad AG, Seeman MV. 1998. Quality of life measurement in schizophrenia: reconciling the quest for subjectivity with the question of reliability. Psychol Med 28: 165-172.
14. Young JL, Zonana HV, Shepler L. 1986. Medication noncompliance in schizophrenia: codification and update. Bull Am Acad Psychiatry & the Law 14: 105-122.